HDL-C predictive of CV events in statin users

Author：

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1609, 2007-01, pp. : 17-17

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Lean Times Looming in the Lipid-Lowering Market: Statin Slump Certain But Hope for HDL-C Drugs

By Adis International Limited

Pharmaceutical & Diagnostic Innovation, Vol. 4, Iss. 11, 2006-01 ,pp. : 7-9

Adis International

Access to resources Recommend Favorite

New Drugs for HDL-C Disorders: The Beginning

Current Medicinal Chemistry, Vol. 21, Iss. 25, 2014-08 ,pp. : 2947-2951

Bentham Science Publishers

Access to resources Recommend Favorite

CV events with NSAIDs: risk high in young rofecoxib users

Reactions Weekly, Vol. 1, Iss. 1210, 2008-01 ,pp. : 3-3

Adis International

Access to resources Recommend Favorite

Treating High Density Lipoprotein Cholesterol (HDL-C): Quantity Versus Quality

Current Pharmaceutical Design, Vol. 19, Iss. 21, 2013-06 ,pp. : 3841-3857

Bentham Science Publishers

Access to resources Recommend Favorite

The clinical impact of pitavastatin: comparative studies with other statins on LDL-C and HDL-C

By Teramoto Tamio

Expert Opinion on Pharmacotherapy, Vol. 13, Iss. 6, 2012-04 ,pp. : 859-865

Informa Healthcare

Access to resources Recommend Favorite